

# PredicineBEACON™

CLIA Validated Personalized, Actionable MRD Assay

Highly sensitive and actionable Molecular Residual Disease (MRD) detection leveraging baseline tissue or liquid biopsy samples

# 50

Up to 50 personalized mutations


# 500

Actionable and hotspot mutations tracked

# ≥0.0025%

Tumor Fraction


## PredicineBEACON™ - Detect MRD Earlier



## Methods and Reporting

- Flexibility in baseline profiling: tissue or liquid biopsy (including blood, plasma, and urine)
- Sensitive MRD detection: limit of detection as low as 0.0025% tumor fraction based on 60ng cfDNA input
- Includes genome-wide copy number changes including copy number reduction
- Longitudinally tracks up to 50 personalized mutations
- Includes analysis of 500 actionable hotspot mutations

## Workflow



# PredicineBEACON addresses the challenges faced by conventional MRD assays



## Tissue Agnostic Solution

Baseline analysis can be obtained via blood, urine, or tissue



## Multi-Dimensional MRD Detection

Detects changes including single nucleotide variants (SNVs), copy number variations (CNVs), and DNA rearrangements



## High Sensitivity







Identify alterations missed by less sensitive assays with an LoD of 0.0025% tumor fraction



## Actionable MRD Result

Upon recurrence, hotspot mutation analysis can provide clinically actionable results to guide treatment decisions

## Case Studies: Validated clinical utility across multiple indications, substantiated by peer-reviewed publications



© 2025 Predicine, Inc. All rights reserved. All trademarks are the property of Predicine, Inc. or their respective owners.

For Research Use Only. Not for use in diagnostic procedures.

